表 1.
132例患者的临床资料[n (%)]
Clinical characteristics of the 132 study patients [n (%)]
| Characteristics | All (n=132) | EGFR positive (n=72) | EGFR negative (n=60) | P |
| PFS: progression-free survival; PR: partial response; SD: stable disease; PD: progressive disease; EGFR-TKIs: epidermal growth factor receptor tyrosine kinase inhibitor. | ||||
| Gender | 0.382 | |||
| Male | 64 (48.5) | 32 (44.4) | 32 (53.3) | |
| Female | 68 (51.5) | 40 (55.6) | 28 (46.7) | |
| Age [median (IQR)] | 63 (54-74) | 58 (41-75) | 59.5 (43-70) | |
| Smoking status | 0.240 | |||
| Current/Former | 35 (26.5) | 16 (22.2) | 19 (31.7) | |
| Never | 97 (73.5) | 56 (77.8) | 41 (68.3) | |
| Histology | > 0.999 | |||
| Adenocarcinoma | 131 (99.2) | 71 (98.6) | 60 (100.0) | |
| Large cell | 1 (0.8) | 1 (1.4) | 0 (0.0) | |
| EGFR-TKIs | < 0.001 | |||
| Gefitinib | 32 (24.2) | 29 (40.3) | 3 (5.0) | |
| Erlotinib | 12 (9.1) | 9 (12.5) | 3 (5.0) | |
| Icotinib | 38 (28.8) | 29 (40.3) | 9 (15.0) | |
| Osimertinib | 2 (1.5) | 2 (2.8) | 0 (0.0) | |
| Not used | 48 (36.4) | 3 (4.2) | 45 (75.0) | |
| Response to EGFR-TKIs | 0.001 | |||
| PR+SD | 23 (85.2) | 23 (95.8) | 0 (0.0) | |
| PD | 4 (14.8) | 1 (4.2) | 3 (100.0) | |
| PFS during EGFR-TKIs treatment (mon, median, 95%CI) | 10.3 (8.9, 11.8) | 11.0 (8.9, 13.1) | 1.0 (0.7, 1.3) | < 0.001 |